ArticleFrontiers in neurology
Clinical features of chronic inflammatory demyelinating polyneuropathy: a single-center experience with 33 patients.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy with heterogeneous clinical presentations. Although several clinical subtypes, including typical and variants, have been described, evidence regarding their distribution and treatment outcomes remains limited, particularly for CIDP variants. Methods: We retrospectively analyzed 33 consecutive patients diagnosed with CIDP at Kumamoto University Hospital between January 2020 and March 2025. Clinical data included demographic characteristics, disease duration, subtype classification, electrophysiological and cerebrospinal fluid (CSF) findings, imaging findings, treatment details, and treatment responsiveness. Subtypes were classified according to the 2021 EAN/PNS diagnostic criteria. Treatment responsiveness was defined as objective improvement confirmed by at least two neurologists. Results: Among the 33 patients, 36.4% had typical CIDP and 63.6% had CIDP variants, including distal (39.4%), multifocal (15.2%), motor (3.0%), and sensory (6.0%) subtypes. Distal CIDP was the most frequent subtype. Patients with multifocal CIDP experienced the longest diagnostic delays (mean, 4.6 years) due to fewer demyelinating findings on electrophysiological studies. The MRC sum score was lowest in typical CIDP, suggesting greater disease severity. Intravenous immunoglobulin (IVIg) demonstrated high efficacy across all subtypes, including multifocal CIDP, in contrast to previous reports of lower responsiveness. During a mean follow-up period of 5.1 years, 78.8% of patients required maintenance therapy, most commonly IVIg and corticosteroids. No changes in clinical subtypes were observed during follow-up. Conclusion: In this single-center study, variants outnumbered typical CIDP, reflecting the case mix at a specialized tertiary referral center. Multifocal CIDP showed the longest diagnostic delays. IVIg demonstrated high efficacy across subtypes, including multifocal CIDP, contrasting with previous reports. These findings highlight the importance of improving diagnostic accuracy and establishing individualized long-term treatment strategies for CIDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.